About Us
Nanophysics & Beyond
Curadigm
The Management
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Corporate | Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO
Scientific Clinical | NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma
23 March 2017
Financial | Nanobiotix successfully completes approx. EUR 25.1 million private placement of new shares
7 April 2017
Corporate | Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO
Published by
Candice Teo
on
4 April 2017
Download pdf
No translations available for this page
